Cr Pharmaceutical
Cr Pharmaceutical, officially known as China Resources Pharmaceutical Group Limited, is a leading player in the pharmaceutical preparation manufacturing industry, headquartered in Hong Kong. Established in 1992, the company has made significant strides in the healthcare sector, focusing on the development, production, and distribution of a wide range of pharmaceutical products.
With a strong presence in major operational regions across China and beyond, Cr Pharmaceutical is renowned for its innovative drug formulations and high-quality healthcare solutions. The company’s core offerings include prescription medications, over-the-counter products, and traditional Chinese medicines, distinguished by their commitment to research and development.
Recognised for its market leadership, Cr Pharmaceutical has achieved numerous accolades, solidifying its reputation as a trusted name in the pharmaceutical industry. Its dedication to quality and innovation continues to drive its success in meeting the evolving needs of healthcare providers and patients alike.
-7 vs industry average
Cr Pharmaceutical’s score of 31 is lower than 46% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Cr Pharmaceutical?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Emissions trajectory 2020 – 2027
Reported emissions
Scope 3 accounts for ••• of total emissions.
Cr Pharmaceutical's reported carbon emissions
CR Pharmaceutical, a pharmaceutical preparation manufacturer headquartered in Hong Kong, has disclosed its carbon emissions for several years, with Scope 1 and Scope 2 data available. For 2024, the company reported total Scope 1 and 2 emissions of approximately 722,459,800 kg CO2e, comprising 175,023,130 kg CO2e for Scope 1 and 547,436,670 kg CO2e for Scope 2. This represents a slight decrease from 2023, when total Scope 1 and 2 emissions were approximately 725,648,620 kg CO2e.
CR Pharmaceutical's climate commitments include a long-term goal of achieving carbon neutrality by 2050, encompassing both Scope 1 and Scope 2 emissions. Furthermore, the company aims to reduce its carbon dioxide emission intensity by 10% by the end of the 14th Five-Year Plan period (2025), compared to a 2020 baseline. Alongside this, they target an 8% reduction in comprehensive energy consumption per unit of added value by the same period.
It's important to note that CR Pharmaceutical's emissions data and climate targets are cascaded from its parent company, China Resources Pharmaceutical Group Limited, where CR Pharmaceutical is a current subsidiary. The company has not yet disclosed Scope 3 emissions data, with purchased goods and services identified as a missing data point.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Cr Pharmaceutical’s Climate Goals (2030 & 2050)
4 goals2050
We aim to achieve carbon neutrality by 2050
We aim to achieve carbon neutrality by 2050.
2030
62% reduction in total GHG
Vs 2019 baseline. Validated by SBTi. Includes full supply chain.
2040
50% reduction in Scope 3 intensity
Across purchased goods and services and logistics.
See all 4 climate goals
Already have an account? Sign in now
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Emissions comparison with industry peers
View similar organisationsUsage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project